THIS WEBSITE USES COOKIES
We use cookies to personalise content, to provide social media features, and to analyse our traffic. By choosing 'allow all cookies', you consent to our cookies.
To find out more, read our privacy policy and cookie policy.
POLINA’s new key enabling technology will give Europe`s important medical industries an edge to deliver safer, biocompatible, multifunctional implantable devices and R&D tools
POLINA’S KEY TO DELIVER BIOCOMPATIBLE DEVICES:
POLINA will shift the current paradigm by adapting high-resolution photolithography for the structuring of functional, biocompatible materials with high geometrical precision directly from natural amino acids. It will overcome limitations of the current gold standard extrusion processing of biocompatible polymers, which cannot realise enough structural precision to move the technology into this new era.
LONG-TERM VISION:
> Develop a key enabling technology that will underpin the set-up of a biolithographic industry, like the current semiconductor industry, for medical devices based on natural amino acid feedstocks.
> Encourage a change in the existing semiconductor and electronics industry towards the use of greener lithographic feedstock materials (amino acids) and an overall more sustainable workflow.
To combine a novel, light-sensitive amino acid materials platform with industrially established and emerging photolithographic techniques. It constitutes a high-risk approach on all levels (materials, processing and their implementation), which is necessary to deliver a high-gain revolutionary technology for next-generation micro-structured materials that can transform the medical device and electronics sectors. POLINA aims to develop and demonstrate this ground-breaking technology for fabricating macro and micro-structured precision manufacturing, ready for validation and upscaling in laboratory, industry and clinical settings.
Develop a robust synthetic protocol for the photo-induced formation of PAAs in short times (1-10s) by testing novel photobase initiators.
Integrate the new chemistry into existing lithographic process flows to allow the fabrication of PAA structures with increasing structural and dimensional complexity from 2D to 3D and from macro to sub-micron scales.
Explore the application of the lithographic PAA platform technology in proof-of-concept studies in three key translatable technologies.
Develop and execute a commercialisation roadmap to protect and commercially exploit intellectual property generated in the project and communicate the results following an Open Science strategy to maximise outreach.
is devoted to the development and optimisation of a photopolymerisation process suitable for the ring-opening polymerisation of amino acid NCAs. This will mainly apply expertise of organic and polymer synthesis combined with material science.
will apply the protocols developed in WP1 and demonstrate their suitability photolithographic patterning and scaffold printing.
will focus on the proof-of-concept integration of PAA structures into medical devices and tools and their performance evaluation.
deal with Coordination & Management and Dissemination & Exploitation, respectively.
deal with Coordination & Management and Dissemination & Exploitation, respectively.
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them.
The project is also supported by the Swiss State Secretariat for Education, Research and Innovation (SERI).